Unmet need in inadequately controlled asthma

Respirology

Volumn 12, Issue SUPPL. 3, 2007, Pages

  Beasley, Richard ^a  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

Author keywords

Asthma; Morbidity; Mortality; Omalizumab; Prevalence

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E; OMALIZUMAB;

ASTHMA; CONFERENCE PAPER; ECONOMIC ASPECT; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SELF CARE;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; AUSTRALIA; COST OF ILLNESS; HAZARDOUS SUBSTANCES; HEALTH CARE COSTS; HUMANS; IMMUNOGLOBULIN E; NEEDS ASSESSMENT; PREVALENCE; RISK FACTORS;

EID: 35448989815     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2007.01046.x     Document Type: Conference Paper

References (7)

1. AIHW Australian Centre for Asthma Monitoring. Asthma in Australia 2005. AIHW Asthma Series 2. AIHW cat no. ACM6. AIHW, Canberra, 2005.
2. Masoli M, Fabian D, Holt S, Beasley R. Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004 59 : 469 78.
3. Beasley R, Crane J, Lai CKW, Pearce N. Prevalence and etiology of asthma. J. Allergy Clin. Immunol. 2000 105 : S466 72.
4. Asher MI, Anderson HR, Stewart AW, Crane J, Ait-Khaled N et al. Worldwide variations in the prevalence of asthma symptoms: ISAAC. Eur. Respir. J. 1998 12 : 315 35.
5. Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P et al. Asthma severity and medical resource utilisation. Eur. Respir. J. 2004 23 : 723 9.
6. Rea HH, Scragg R, Jackson R, Beaglehole R, Fenwick J et al. A case-control study of deaths from asthma. Thorax 1986 41 : 833 9.
7. Global Initiative for Asthma. Global strategy for asthma management and prevention, 2006. [Accessed 10 December 2005.] Available from URL: http://www.ginasthma.org.